<DOC>
	<DOCNO>NCT00712114</DOCNO>
	<brief_summary>The purpose pilot , exploratory study evaluate safety , tolerance , pharmacokinetics potential anti-inflammatory activity investigational agent , HE3286 , administer orally 29 day patient rheumatoid arthritis take stable dose methotrexate .</brief_summary>
	<brief_title>Safety , Tolerance , Pharmacokinetics Activity HE3286 Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description>This Phase I/II , open label , dose range study safety , tolerance , anti-inflammatory activity HE3286 patient rheumatoid arthritis . Patients receive study treatment ( one three open label dos ) addition current stable dose methotrexate . Safety ( via monitoring vital sign , physical examination change , ECG result , laboratory result , adverse event ) , pharmacokinetics profile ( HE3286 methotrexate ) anti-inflammatory activity assess treatment period 29 day .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Dehydroepiandrosterone</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<criteria>Main Male female patient 1875 year age Patient stable active disease stable dose methotrexate least 30 day prior Day 1 Patient normal thyroid stimulate hormone ( TSH ) level without thyroid replacement therapy Patient willing abstain consume grapefruit containing product 24 hour prior dose end study may affect pharmacokinetic measurement Patient experience renal liver disease history and/or base laboratory result Patient experience acute cardiac disease within 6 month prior Screening Patient must provide voluntary , write , informed consent prior screen evaluation able follow verbal write instruction . Main Functional status class IV accord The American College Rheumatology ( ACR ) criteria Patient history clinically significant cardiovascular disease ( include coronary artery disease ) , clinically significant hepatic , respiratory renal abnormality , clinically significant endocrine disorder ( include diabetes ) Patient active Tuberculosis ( TB ) evidence latent TB without previous adequate therapy Systemic autoimmune disorder ( include , limited , systemic lupus erythematosus , inflammatory bowel disease , scleroderma , inflammatory myopathy , mixed connective tissue disease overlap syndrome ) Inflammatory joint disease RA Patient receive follow immunosuppressive drug : Etanercept within 1 month Day 1 ; Abatacept , adalimumab , infliximab , leflunomide , imuran , cyclosporin , anakinra , sulfasalazine , bextra , celebrex gold within 2 month Day 1 biological agent 6 half life , whichever great ; Rituximab within 1 year Day 1 Patient bed wheelchair bound Patients take prednisone within 2 week prior Screening Patient require receive follow within thirty ( 30 ) day prior screen visit : interleukin , steroid ( i.e. , anabolic steroid , glucocorticoid ) , hormone replacement therapy ( except stable lowdose HRT least 6months prior screening ) , birth control pill , anticancer chemotherapeutic agent ( except methotrexate ) , metabolic inhibitor ( except methotrexate ) , concomitant medication prolong QT/QTc interval Patient clinically significant abnormality laboratory result Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>phase I</keyword>
	<keyword>safety</keyword>
	<keyword>tolerance</keyword>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>methotrexate</keyword>
	<keyword>anti-inflammatory</keyword>
</DOC>